Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.

Adenosine Monophosphate / analogs & derivatives Alanine / analogs & derivatives Alveolar Epithelial Cells / cytology Antiviral Agents / analysis Betacoronavirus / drug effects COVID-19 Cell Line Coronavirus Infections / drug therapy Cysteine Proteinase Inhibitors / analysis Dose-Response Relationship, Drug Drug Evaluation, Preclinical Drug Repositioning Drug Synergism Gene Expression Regulation / drug effects Humans Hydrazones Induced Pluripotent Stem Cells / cytology Models, Biological Morpholines / analysis Pandemics Pneumonia, Viral / drug therapy Pyrimidines Reproducibility of Results SARS-CoV-2 Small Molecule Libraries / analysis Triazines / analysis Virus Internalization / drug effects Virus Replication / drug effects COVID-19 Drug Treatment

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
10 2020
Historique:
received: 20 04 2020
accepted: 17 07 2020
pubmed: 25 7 2020
medline: 6 10 2020
entrez: 25 7 2020
Statut: ppublish

Résumé

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of the severe pneumonia-like disease coronavirus disease 2019 (COVID-19)

Identifiants

DOI: 10.1038/s41586-020-2577-1 PMID: 32707573 PMC: PMC7603405
pubmed: 32707573
doi: 10.1038/s41586-020-2577-1
pii: 10.1038/s41586-020-2577-1
pmc: PMC7603405
mid: NIHMS1613359
doi:

Substances chimiques

Antiviral Agents 0
Cysteine Proteinase Inhibitors 0
Hydrazones 0
Morpholines 0
Pyrimidines 0
Small Molecule Libraries 0
Triazines 0
remdesivir 3QKI37EEHE
Adenosine Monophosphate 415SHH325A
apilimod GFW2K84S4L
Alanine OF5P57N2ZX

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113-119

Subventions

Organisme : NCI NIH HHS
ID : P30 CA030199
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA023100
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI118610
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI135972
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM132024
Pays : United States

Références

Curr Trop Med Rep. 2020;7(2):61-64
pubmed: 32219057
Antiviral Res. 2019 Sep;169:104558
pubmed: 31302150
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
J Med Chem. 2014 Mar 27;57(6):2393-412
pubmed: 24568342
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4453-8
pubmed: 25831516
PLoS One. 2018 Sep 21;13(9):e0204532
pubmed: 30240452
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Virol. 2012 Sep;86(18):10112-22
pubmed: 22787216
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Lancet Microbe. 2020 May;1(1):e14-e23
pubmed: 32835326
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Amino Acids. 2007 Jul;33(1):129-35
pubmed: 16998715
IDrugs. 2007 Jan;10(1):53-9
pubmed: 17187316
Chem Biol. 2013 Jul 25;20(7):912-21
pubmed: 23890009
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1636-1645
pubmed: 32726565
PLoS Negl Trop Dis. 2017 Feb 3;11(2):e0005373
pubmed: 28158186
Genome Biol. 2014;15(12):550
pubmed: 25516281
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
J Korean Med Sci. 2020 Feb 24;35(7):e84
pubmed: 32080990
Virology. 2018 Jan 1;513:17-28
pubmed: 29031163
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10750-10755
pubmed: 30282735
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Clin Invest. 2013 Nov;123(11):4950-62
pubmed: 24135142
Nat Commun. 2019 Jan 10;10(1):120
pubmed: 30631056
Genome Med. 2012 Mar 30;4(3):27
pubmed: 22494857
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Nat Protoc. 2019 Dec;14(12):3303-3332
pubmed: 31732721
Proc Natl Acad Sci U S A. 2017 May 2;114(18):4679-4684
pubmed: 28416697
Front Immunol. 2020 Jul 10;11:1664
pubmed: 32754161
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24
pubmed: 18852458
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5684-8
pubmed: 18796354
Clin Infect Dis. 2020 Jul 28;71(15):841-843
pubmed: 32047895
J Virol Methods. 2010 Nov;169(2):365-74
pubmed: 20709108
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25
pubmed: 15144898
PLoS Negl Trop Dis. 2017 Apr 12;11(4):e0005540
pubmed: 28403145
Medicine (Baltimore). 2020 Nov 25;99(48):e23357
pubmed: 33235105

Auteurs

Laura Riva (L)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Shuofeng Yuan (S)

State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.

Xin Yin (X)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
ORCID: 0000-0003-2357-6718

Laura Martin-Sancho (L)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Naoko Matsunaga (N)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Lars Pache (L)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
ORCID: 0000-0002-4193-1042

Sebastian Burgstaller-Muehlbacher (S)

Center for Integrative Bioinformatics Vienna, Max Perutz Laboratories, University of Vienna and Medical University of Vienna, Vienna, Austria.
ORCID: 0000-0003-4640-3510

Paul D De Jesus (PD)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Peter Teriete (P)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Mitchell V Hull (MV)

Calibr at Scripps Research, La Jolla, CA, USA.

Max W Chang (MW)

Department of Medicine, University of California, San Diego, La Jolla, CA, USA.

Jasper Fuk-Woo Chan (JF)

State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.

Jianli Cao (J)

State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.

Vincent Kwok-Man Poon (VK)

State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.

Kristina M Herbert (KM)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Kuoyuan Cheng (K)

Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
Biological Sciences Graduate Program, University of Maryland, College Park, MD, USA.

Tu-Trinh H Nguyen (TH)

Calibr at Scripps Research, La Jolla, CA, USA.

Andrey Rubanov (A)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Yuan Pu (Y)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Courtney Nguyen (C)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Angela Choi (A)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Raveen Rathnasinghe (R)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Michael Schotsaert (M)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0003-3156-3132

Lisa Miorin (L)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Marion Dejosez (M)

Huffington Foundation Center for Cell-based Research in Parkinson's Disease, Department for Cell, Regenerative and Developmental Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Thomas P Zwaka (TP)

Huffington Foundation Center for Cell-based Research in Parkinson's Disease, Department for Cell, Regenerative and Developmental Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Ko-Yung Sit (KY)

Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.

Luis Martinez-Sobrido (L)

Texas Biomedical Research Institute, San Antonio, TX, USA.
ORCID: 0000-0001-7084-0804

Wen-Chun Liu (WC)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Kris M White (KM)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0003-0889-0506

Mackenzie E Chapman (ME)

Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.

Emma K Lendy (EK)

Department of Biochemistry, Purdue University, West Lafayette, IN, USA.

Richard J Glynne (RJ)

Inception Therapeutics, San Diego, CA, USA.

Randy Albrecht (R)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0003-4008-503X

Eytan Ruppin (E)

Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.

Andrew D Mesecar (AD)

Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.
Department of Biochemistry, Purdue University, West Lafayette, IN, USA.
ORCID: 0000-0002-1241-2577

Jeffrey R Johnson (JR)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Christopher Benner (C)

Department of Medicine, University of California, San Diego, La Jolla, CA, USA.

Ren Sun (R)

Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
ORCID: 0000-0002-8628-7019

Peter G Schultz (PG)

Calibr at Scripps Research, La Jolla, CA, USA.

Andrew I Su (AI)

Department of Integrative, Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
ORCID: 0000-0002-9859-4104

Adolfo García-Sastre (A)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0002-6551-1827

Arnab K Chatterjee (AK)

Calibr at Scripps Research, La Jolla, CA, USA. achatterjee@scripps.edu.
ORCID: 0000-0001-5171-7982

Kwok-Yung Yuen (KY)

State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China. kyyuen@hku.hk.
Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China. kyyuen@hku.hk.
Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China. kyyuen@hku.hk.
ORCID: 0000-0002-2083-1552

Sumit K Chanda (SK)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. schanda@sbpdiscovery.org.
ORCID: 0000-0001-9399-7927

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Ribonucléotides › Nucléotides adényliques › AMP › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Alanine › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Cellules › Cellules épithéliales › Pneumocytes › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Nidovirales › Infections à Coronaviridae › Infections à coronavirus › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéases › Inhibiteurs de la cystéine protéinase › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Repositionnement des médicaments › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Interactions médicamenteuses › Synergie des médicaments › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Composés chimiques organiques › Hydrazines › Hydrazones › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches pluripotentes › Cellules souches pluripotentes induites › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Oxazines › Morpholines › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Pandémies › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Reproductibilité des résultats › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Bibliothèques de petites molécules › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Triazines › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Pénétration virale › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › Discovery of SARS-CoV-2 antiviral drugs...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Traitements médicamenteux de la COVID-19 › Discovery of SARS-CoV-2 antiviral drugs...